'We have made it for fifteen years without a problem' used to be written up as a validation report.
The method was called retrospective validation: take the last twenty or thirty batch records, tabulate yields and assay results, and conclude that the process is validated.
EU GMP Annex 15, in its 2015 text, closes that door twice, in the general section and again under process validation (section 5): retrospective validation is no longer an acceptable approach. The same section says a traditional process should undergo prospective validation, wherever possible, before the product is certified. Concurrent validation is kept for exceptional circumstances, and the decision must be justified and documented in the validation master plan.
Two things were missing from the old report. Nobody set acceptance criteria before the batches were made, and the critical parameters were whatever the batch record happened to capture.
The batch history still has a job. The annex says ongoing process verification should be used throughout the product lifecycle, and thirty batches of trended data are a good start for it. The FDA process validation guidance of 2011 points the same way for legacy products: the work would likely begin with its Stage 3, continued process verification.
If a retrospective report is still listed as the validation for one of your products, that is the one to re-plan first.
Topics
Industries



